Ischemia Care's technology is based upon proprietary biomarkers using RNA expression to stratify ischemic stroke patients by cause. The first application the company is pursuing is stratification of ischemic stroke patients by cause, with initial adoption being in the 40% of ischemic stroke patients where cause is unknown or "cryptogenic". This is important because a blood test for cause of stroke, used in the acute and hospital setting to enable clinicians to better identify cause would ensure the appropriate treatment pathways to prevent recurrent are adopte prior to discharge. Recurrent strokes are often more massive, debilitating, and costly.
Ischemia Care's diagnostic development plans include several future directions based upon clear clinical need and reimbursement:
First, complete the development and clinical launch of ISCDX, a blood test for cause of stroke, differentaiting cardioembolic from atheroembolic cause of stroke with intial adoption in "cryptogenic" cases (280,000 US events per year).
Second, a blood test for TIA. The company has early published data on biomarkers to identify clinically diagnosed TIAs. TIAs are different from stroke in that the neurological deficit is transient in nature making a clincial diagnosis difficult. It is important to distinguish TIA's from other similar events (sincope, seizures, fainting) as TIA's carry a higher subsequest stroke risk. There are an estimated 500,000 TIAs in the US each year, and an estimated 2-3 times the amount of similar events.
Third, a blood test for lacunar stroke, which are small vessel strokes within the brain with 15,000 US event per year
Concurrent with all of the above is the underlying development of "point or care" applications.
Finally, this technology can also be use as a tool to develop new treatment regimens, therapeutics, point of care diagnostics, and interventional devices.